

Buy & Bill and Specialty Pharmacy Process



Gel-One® and Visco-3™ are physician-administered treatments, which are typically covered under the medical benefit by most health insurance plans. However, coverage details and requirements can vary between patients, so the specific steps involved may differ based on individual circumstances.

Confirm Patient Coverage

1

Medicare Part B - Fee for Service - Buy & Bill is required

- Gel-One & Visco-3 are open access
- No restrictions at the local level
- No prior authorization is required
- Patient is eligible to receive treatment immediately
- Gel-One billing code (J7326)
- Visco-3 billing code (J7321)

Commercial and Medicare Advantage - Buy & Bill and Specialty Pharmacy options are available

- Gel-One & Visco-3 access varies
- Coverage, authorization and fees will vary
- Patient Access Solution is available to assist with:
 - Determining coverage
 - Verifying benefits
 - Obtaining prior authorizations when needed

2

Order Gel-One or Visco-3

Obtain either Gel-One or Visco-3 through your standard Buy & Bill process or through your Specialty Pharmacy of choice (or the specialty pharmacy required by the insurance plan)

3

Schedule the Patient's Injection

You may schedule the patient's treatment once the benefits have been obtained, you have confirmed the patient meets payer requirements and either Gel-One or Visco-3 has been ordered.

4

Patient's Treatment Day

Collect patient's copay or coinsurance on the day of the patient's appointment. Make sure to properly document the treatment and have the documents ready should the payer request them.

5

Submit the Claim

Submit the claim to the payer along with all necessary documentation.

6

Reconcile Reimbursement

Confirm that the payment matches your expectations. If the claim is denied or only partially paid, you can contact our Patient Access Solutions team at 855-200-2760 for assistance with a claims review and/or denial support.

Current Procedural Terminology (CPT®) is copyright © 2024 by the American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association

Zimmer Biomet Coding Reference Guide Disclaimer

Providers, not Zimmer Biomet, are solely responsible for ensuring compliance with Medicare, Medicaid, and all other third-party payer requirements, as well as accurate coding, documentation and medical necessity for the services provided. Before filing claims, providers should confirm individual payer requirements and coverage/medical policies. The information provided in this document is not legal or coding advice; it is general reimbursement information for reference purposes only. It is important to note that Zimmer Biomet provides information obtained from third-party authoritative sources and such sources are subject to change without notice, including as a result in changes in reimbursement laws, regulations, rules, and policies. This information may not be all-inclusive, and changes may have occurred subsequent to publication of this document. This document represents no promise or guarantee by Zimmer Biomet regarding coverage or payment for products or procedures by Medicare or other payers. Inquiries can be directed to the provider's respective Medicare Administrative Contractor, or to appropriate payers. Zimmer Biomet specifically disclaims liability or responsibility for the results or consequences of any actions taken in reliance on information in this guide.

Gel-One:

Indications For Use

Gel-One Hyaluronate is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to non-pharmacologic therapy, non-steroidal anti-inflammatory drugs (NSAIDs) or simple analgesics, e.g., acetaminophen.

Important Safety Information

Before using Gel-One Hyaluronate, ask your patients if they are allergic to hyaluronan products, cinnamon, or products from birds such as feathers, eggs, and poultry. Gel-One Hyaluronate is only for injection into the knee, performed by a doctor or other qualified health care professional. Gel-One Hyaluronate injection should not be used in the presence of a skin disease or infection around the area where the injection will be given. Gel-One Hyaluronate has not been tested to show pain relief in joints other than the knee and for conditions other than OA. Gel-One Hyaluronate has not been tested in patients who are pregnant, mothers who are nursing, or anyone under the age of 21. Strenuous or prolonged weight-bearing activities after treatment are not recommended. The effectiveness of repeat treatment cycles of Gel-One Hyaluronate has not been established. The side effects most commonly seen after injection of Gel-One Hyaluronate in the clinical trial were knee pain, swelling, and/or knee effusion. These reactions are generally mild and do not last long. For complete instructions for use, see the package insert.

VISCO-3:

Indications For Use

VISCO-3 Sodium Hyaluronate is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.

Important Safety Information

Before using VISCO-3 Sodium Hyaluronate, ask your patients if they are allergic to hyaluronan products, or products from birds such as feathers, eggs, and poultry. Do not administer to patients with known hypersensitivity to sodium hyaluronate preparations. Use caution when injecting VISCO-3 Sodium Hyaluronate into patients who are allergic to avian proteins, feathers and egg products. VISCO-3 Sodium Hyaluronate is only for injection into the knee, performed by a doctor or other qualified health care professional. VISCO-3 Sodium Hyaluronate injection should not be used in the presence of a skin disease or infection around the area where the injection will be given. VISCO-3 Sodium Hyaluronate has not been tested to show pain relief in joints other than the knee and for conditions other than OA. VISCO-3 Sodium Hyaluronate has not been tested in patients who are pregnant, mothers who are nursing, or anyone under the age of 21. Strenuous or pro-longed weight-bearing activities after treatment are not recommended. The effectiveness of repeat treatment cycles of VISCO-3 Sodium Hyaluronate has not been established. The side effects most commonly seen after injection of VISCO-3 Sodium Hyaluronate in the clinical trial were knee pain, swelling, and/or fluid build-up around the knee. These reactions are generally mild and do not last long. Other conditions, including but not limited to skin redness and rash, knee stiffness was also reported. For complete instructions for use, see the package insert and visit www.zimmerbiomet.com.

This material is intended for health care professionals. For product information, including indications, contraindications, warnings, precautions, potential adverse effects, and patient counseling information, see the package insert or contact your local representative; visit www.zimmerbiomet.com.

©2025 Zimmer Biomet